The burden of non-tuberculous mycobacterial (NTM) disease is increasing worldwide. The disease shares clinicoradiological features with tuberculosis (TB), Nocardia and several fungal diseases, and its diagnosis is frequently delayed. The present study was performed to determine the frequency of NTM disease among TB suspects in a tertiary care centre in north India.
known to occur except in patients with cystic fibrosis (CF) due to Mycobacterium abscessus 1 . Similar to TB, lung is the most common site of involvement in NTM disease. The pulmonary disease frequently occurs in the previously damaged lungs due to bronchiectasis, TB, CF, chronic obstructive pulmonary disease and pneumoconiosis 2 . NTM disease may also manifest as disseminated type, especially in individuals with congenital or acquired immune defects such as HIV/AIDS and as localized disease such as cutaneous involvement 3, 4 . Children frequently present with cervical lymphadenitis 5 .
The exact burden of NTM disease is not known because it is not a reportable disease worldwide including India. Recent years have witnessed an increased reporting of NTM disease worldwide, especially from high-income countries 2 because of several reasons which include (i) increase in environmental NTM sources, (ii) increase in susceptible populations, (iii) low TB disease burden leading to decreased herd immunity, (iv) heightened awareness about NTM disease, (v) availability of better molecular tools for diagnosis of NTM disease, and (vi) hitherto unidentified cause(s) for the increased NTM infections. There is a scarcity of published reports from high TB burden countries including India. The present report describes a prospective study of NTM patients found among TB suspects in a tertiary care hospital in north India.
Material & Methods
The study was conducted prospectively in the department of Internal Medicine at the All India Institute of Medical Sciences (AIIMS), New Delhi, India, between August 2014 to November 2016. Patients included in this study were of either gender, aged more than 12 yr irrespective of their HIV status. Written informed consent was taken from all the study participants, and the study was approved by the Institutional Ethics Committee.
Sample collection and laboratory processing:
Pulmonary and extrapulmonary specimens received from the TB suspects presenting to various outpatient departments and those hospitalized for diagnosis were processed at the Intermediate Reference Laboratory (IRL) of National Capital Region, New Delhi located in the department of Internal Medicine at AIIMS, New Delhi. The IRL is accredited by the Ministry of Health & Family Welfare, Government of India. The American Thoracic Society (ATS) guidelines 6 definitions were used for sample collection and processing. In pulmonary patients, sputum specimens and induced sputum and/or bronchoalveolar lavage (BAL) fluid specimens in those patients who were not able to produce sputum were obtained for diagnosis. From patients who were producing sputum, the specimens were tested twice using two samples obtained on different occasions. For extrapulmonary specimen such as pus, lymph node aspirate and/or biopsy, pleural, pericardial, cerebrospinal fluids, bone marrow specimens were obtained and processed as detailed below.
The acid-fast bacilli (AFB) smear was prepared directly from each sample; the smear microscopy was done using Ziehl-Neelsen staining method as per the standard protocol, and the smear was evaluated under the light emitting diode microscope (Carl Zeiss Microscopy, Germany) 7 . The remaining sample was subjected to standard decontamination protocol (NALC-NAOH method) 8 and the processed sample was subsequently used for culture inoculation on solid (Lowenstein-Jensen) and liquid culture (automated MGIT 960) media.
The Xpert MTB/RIF test was performed using the G4 version of cartridges according to the manufacturer's instructions (Cepheid, Sunnyvale, USA) as described previously 9 . The samples were subsequently inoculated into Mycobacterium Growth Indicator Tube (MGIT 960), a non-radiometric automated isolation system (Becton Dickinson, USA) 8 . The MGIT tube contained 7 ml of 7H9 medium, supplemented with 0.8 ml of oleic acid-albumin-dextrose-catalase and polymyxin B-amphotericin B-nalidixic acid-trimethoprimazlocillin, and the tube was inoculated with 0.5 ml of processed sample 8 . The mycobacterial positive cultures were tested to differentiate between M. tuberculosis and NTM using immunochromatographic assay (ICA) kit (SD MPT64TB Ag kit, Standard Diagnostics, South Korea). ICA-negative culture isolates were further subjected to NTM species identification. The mycolic acid extraction and high performance liquid chromatographic (HPLC) analysis were performed at the National Tuberculosis Institute, Bengaluru, using a previously described protocol 10 . The species identification of NTM isolates was done by the line probe assay (LPA) as per the manufacturer's protocol using GenoType ® Common Mycobacteria/ Additional Species kit (HAIN LifeScience, Germany). The genomic mycobacterial DNA extraction of culture isolates for targeted gene sequencing was done by heat lysis method and amplified using standardized protocols 11 . Further, for the confirmation of species of NTM isolates, targeted amplification of 16S-23S rRNA internal transcribed spacer (ITS) region was performed by polymerase chain reaction (PCR). The amplified 16S-23S rRNA ITS region was sequenced using DNA sequencing with ABI Prism 3130xl Genetic Analyzer (Applied Biosystems, USA). The PCR primers used for the amplification for 16S-23S rRNA ITS region were ITS (Forward) 5'-GAAGTCGTAACAAGGTAGCCG-3' and ITS (Reverse) 3'-GACAGCTCCCCGAGGCTTATCGCA-5' (Sigma-Aldrich, USA) 11 . The PCR product was further examined by gel electrophoresis in two per cent agarose gel. The cycle sequencing was carried out using BigDye Terminator v3.1 cycle sequencing kit (Applied Biosystems, USA), and the products were loaded in the sequencer. The sequencing results were analyzed using BioEdit, a biological sequence alignment editor software (Carlsbad, California, USA), and the alignment was done using Clustal W (Dublin, Ireland).
HIV testing: All patients underwent HIV-1 and HIV-2 testing by the ELISA technique as previously described 12 at the Integrated Counselling and Testing Centre of the hospital after counselling and obtaining written informed consent.
Clinical features and radiological investigations:
Relevant clinical features and laboratory data of all diagnosed patients were recorded in the source notes, subsequently transferred to the case record form and finally entered into the Excel spreadsheet. All relevant clinical and laboratory details were recorded. Radiological findings were independently scored by a radiologist and a chest physician, and in case of discordance, an alternative radiologist resolved the scoring.
Treatment and follow up: All except one patient had active NTM disease and were offered treatment. Benefits of drug treatment versus prolonged treatment and their adverse events (AEs) were discussed with patients before starting the treatment. The drug regimen consisted of oral administration of rifabutin (R) 300 mg/day (typically administered for M. avium complex disease), clarithromycin (C) 500 mg twice daily and ethambutol (E) 15 mg/kg/day up to a maximum of 1.2 g/day. In M. abscessus disease, along with RCE, some additional antibiotics were included in the regimen. All patients with NTM pulmonary disease (NTM-PD) were treated for one year following culture conversion and extrapulmonary NTM (EP-NTM) patients were treated according to clinical, radiological and microbiological responses and were followed up periodically for AEs and serious adverse events (SAEs).
Results
Pulmonary and extrapulmonary specimens from 5409 TB suspects were tested and 42 (0.77%) patients were diagnosed with NTM disease and were treated and followed up till December 2017 ( Fig. 1 ). Clinical and microbiological characteristics of these patients are detailed in Table I . Males (24:18) were frequently affected with this disease. The mean age of NTM patients was 39.7 (SD: 14.4) yr. Of the 42 patients, 34 (80.9%) had NTM-PD. Various predisposing risk factors for NTM-PD are described in Table II . Thirty three (97%) patients had bronchiectasis and 32 of these had a history of pulmonary TB. Two patients had bronchial asthma and one of these had allergic bronchopulmonary aspergillosis with bronchiectasis (ABPA).
Of the eight patients with EP-NTM disease, HIV/AIDS was present in one patient and his CD4 cell count was 644 cells/μl, four had hospital-acquired NTM disease (detailed in Table II ) and another two had NTM disease following trauma.
M. intracellulare (11/34; 32.3%) was the most common NTM isolate followed by M. abscessus (9/34; 26.5%) in NTM-PD. In one patient with bronchial asthma, M. simiae was repeatedly isolated. This patient was not treated as he did not have active disease. Of the 42 NTM patients, 41 were having active NTM disease as per ATS definition 6 . Therefore, it was decided to treat these patients. M. abscessus was treated with additional drugs such as linezolid, amikacin, ciprofloxacin, co-trimoxazole and imipenem. AEs and SAEs are detailed in Table III .
Of the 33 patients with active NTM-PD, five were lost to follow up, 10 patients died, two died due to massive haemoptysis and in eight patients exact cause of drug regimen consisting of imipenem and injectable amikacin. Later, this patient was also treated with antifungal drugs for mucormycosis infection. In one patient with a history of hernia, the infected mesh was surgically removed and the improvement was observed after one month of the drug treatment. One patient with breast abscess was treated for 11 months. The patient with HIV/AIDS declined the prescribed treatment.
Discussion
With wider availability of molecular diagnostic tests for NTM and their identification at species and sub-species level, there has been a renewed interest in this disease. In the past decade, there has been an increase in the reporting of NTM disease 2-4 but most of these reports are from the industrialized world and death could not be ascertained. Three patients declined the treatment and one of these opted for an alternative form of treatment. In 15 NTM-PD patients, there was good response to treatment. All were given one year of treatment after culture conversion. One patient with bronchial asthma and ABPA was hospitalized nearly after one year of cure with acute exacerbation of bronchial asthma and microbiological relapse was ruled out in this case after appropriate microbiological investigations. In EP-NTM patients, treatment duration varied from 1-16 months (median: 12 months; interquartile range: 3-16 months). Surgery was performed in one patient with knee joint arthritis and linezolid was added to his antimycobacterial drug regimen. One patient with chronic osteomyelitis of the left femur had multiple surgeries and received 13 and all of these may not be clinically relevant. There is a scarcity of NTM reporting from the developing countries with high TB burden. Only a handful of studies have been published from India 14-24 . Ironically, most of these have reported microbiological data from TB laboratories involved in isolating NTM.
There is a lack of information on patients' data and in most instances ATS guidelines definition criteria for disease activity have not been applied. Therefore, it was difficult to conclude whether these NTM isolates were just commensals, contaminants or causative agent of disease. In addition, follow up details including drug treatment regimens, AEs and SAEs and disease outcomes were not reported in most of these studies.
A variable prevalence of NTM disease (0.38-27.4%) has been reported from India 14-24 . In the present study, the prevalence of NTM among TB suspects was low (0.77%). Three other studies from large TB centres in India have reported a low NTM disease prevalence among TB suspects, 0.38, 0.8 and 0.86 per cent, respectively 16, 18, 19 . A possible explanation for the low NTM disease prevalence in these studies can be the sample collection from a larger population as these healthcare facilities cover large number of districts in their respective States. Another three Indian studies 14,15,17 reporting higher NTM prevalence were published before the ATS guidelines 6 were released. In other four studies, the prevalence rates were higher as two studies were solely laboratory based 20, 24 , and one was a retrospective study on clinical isolates 21 and the remaining one was in HIV/AIDS patients only 15 .
In the present study, of the 42 patients with NTM infection, 41 fulfilled NTM disease criteria as per ATS definition 6 and one was asymptomatic. The male involvement occurred more frequently and pulmonary involvement was predominantly (34 out of 42 patients; 81%) observed. This involvement was similar to TB where 80 per cent involvement was observed in HIV-negative individuals 25 . Bronchiectasis as sequelae of pulmonary TB was the most common predisposing cause. Only one patient in the EP-NTM group was HIV seropositive.
In the present study, M. intracellulare was the most common NTM isolate followed by M. abscessus among pulmonary patients. This finding was similar to worldwide published reports 2 in patients with pulmonary disease; however, some geographical diversity of NTM species such as M. xenopi and M. szulgai has been observed 26 . M. gordonae is frequently a contaminant or colonizer and rarely produces disease. In this study, this organism was repeatedly isolated from three patients and all had active pulmonary disease. One patient opted for an alternative form of treatment and other two patients died without treatment and the exact cause of death could not be ascertained in these patients.
In the present study, the diagnosis of NTM disease was based on patients' clinical characteristics, radiological features and laboratory results including microbiological and molecular tests. It is to be emphasized that no patient with suspected NTM disease should be empirically treated. Further, mere isolation of NTM does not necessarily indicate an active disease. While treating patients with NTM disease, especially patients with disseminated disease, it is crucial to make assessment of co-morbidities, host-related predisposing factors including immunological perturbations. HIV/AIDS must be ruled out as it requires life-long treatment with highly active antiretroviral treatment. Right nipple trauma sustained during breast feeding § § 1 * One patient had history of bronchial asthma but was asymptomatic for NTM disease and another had asthma with ABPA and bronchiectasis; † In one patient with disseminated NTM disease no underlying immune defect could be found despite extensive investigations; § One patient had post-operative osteomyelitis of the left femur and another had post-fracture suppurative right knee joint arthritis; ** CD4 cell count: 644 cells/µl; ‡ Trauma occurred while ear cleaning, resulting in chronic suppurative otitis media and conductive deafness. Chronic suppurative otitis media with deafness and lower motor neurone type of facial nerve palsy and left optic neuropathy due to orbital cellulitis; § § Patient also had vitamin D deficiency and chronic hypersensitivity pneumonitis due to exposure to domestic pigeons. NTM, non-tuberculous mycobacterial; NTM-PD, NTM pulmonary disease; ABPA, allergic bronchopulmonary aspergillosis; EP-NTM, extrapulmonary NTM In patients with NTM-PD, persistence of clinical symptoms despite culture conversion may be attributed to the underlying permanent abnormalities of the lungs and these abnormalities may also predispose to relapse of NTM infection. In most patients with EP-NTM disease, the drug treatment along with surgical intervention cured patients except one patient with left femur osteomyelitis due to M. abscessus who required prolonged hospitalization for intravenous antibiotics administration in addition to surgery. It was difficult to treat this patient with antibiotics. Eventually, he was administered antifungal treatment. None of the patients in this study had co-infection of NTM and MTB, one patient had co-infection with mucormycosis. It is suggested that co-infection with TB and fungal infection should be diligently searched and ruled out.
Subspecies identification and drug sensitivity testing (DST) of these NTM isolates were not done. This was a limitation of the study. It is important to identify subspecies of M. abscessus as M. abscessus subsp. abscessus is difficult to treat with various combinations of intravenous and oral antibiotics 4 . Another limitation of the study was that the speciation of the NTM was done by single target gene sequencing. A multi-locus gene analysis could have facilitated the NTM identification up to subspecies level and could have provided additional information about the drug resistance in NTM due to mutations in certain genes such as erm (41), 16S rRNA and 23S rRNA especially macrolide and amikacin resistance. The major strengths were the prospective nature of the study, use of ATS definition criteria for NTM disease activity and treatment, NTM species identification by various methods including HPLC, LPA and ITS gene sequencing and follow up while patients were on treatment.
In conclusion, our findings showed a low frequency of NTM disease among TB suspects at a 
